森川 則文Norifumi Morikawa

Last Updated :2019/12/02

所属・職名
大学院医系科学研究科(薬)(薬学)臨床薬物治療学教授
メールアドレス
morikawahiroshima-u.ac.jp

基本情報

学位

  • 博士(薬学)(徳島大学)
  • 薬学修士(徳島大学)

研究分野

  • 医歯薬学 / 薬学 / 医療系薬学

研究キーワード

  • 体内動態
  • 抗癌剤

教育活動

授業担当

  1. 2019年, 学部専門, 1ターム, 臨床医学概論I
  2. 2019年, 学部専門, 3ターム, 臨床医学概論III
  3. 2019年, 学部専門, 1ターム, 薬剤経済学
  4. 2019年, 学部専門, 3ターム, 臨床評価学
  5. 2019年, 学部専門, 3ターム, 日本薬局方演習
  6. 2019年, 学部専門, 3ターム, 臨床事前実習
  7. 2019年, 学部専門, 通年, 基礎研究I
  8. 2019年, 学部専門, 通年, 基礎研究II
  9. 2019年, 学部専門, 通年, 臨床研究I
  10. 2019年, 学部専門, 通年, 臨床研究II
  11. 2019年, 学部専門, 通年, 臨床研究III
  12. 2019年, 修士課程・博士課程前期, セメスター(前期), 生命・医療倫理学
  13. 2019年, 修士課程・博士課程前期, セメスター(前期), 生命・医療倫理学
  14. 2019年, 修士課程・博士課程前期, セメスター(前期), 生命・医療倫理学
  15. 2019年, 修士課程・博士課程前期, セメスター(前期), 生命・医療倫理学
  16. 2019年, 修士課程・博士課程前期, セメスター(前期), 生命・医療倫理学
  17. 2019年, 修士課程・博士課程前期, セメスター(前期), 生命・医療倫理学
  18. 2019年, 修士課程・博士課程前期, セメスター(前期), 生命・医療倫理学
  19. 2019年, 修士課程・博士課程前期, セメスター(前期), 生命・医療倫理学
  20. 2019年, 博士課程・博士課程後期, セメスター(前期), 生命・医療倫理特論
  21. 2019年, 博士課程・博士課程後期, セメスター(前期), 生命・医療倫理特論
  22. 2019年, 修士課程・博士課程前期, セメスター(前期), 薬物治療学特論
  23. 2019年, 修士課程・博士課程前期, セメスター(前期), 薬物治療学特論演習
  24. 2019年, 修士課程・博士課程前期, セメスター(後期), 薬物治療学特論演習
  25. 2019年, 修士課程・博士課程前期, セメスター(前期), 薬物治療学特別実習
  26. 2019年, 修士課程・博士課程前期, セメスター(後期), 薬物治療学特別実習
  27. 2019年, 博士課程・博士課程後期, セメスター(前期), 臨床薬物治療学特別演習
  28. 2019年, 博士課程・博士課程後期, セメスター(後期), 臨床薬物治療学特別演習
  29. 2019年, 博士課程・博士課程後期, セメスター(前期), 臨床薬物治療学特別実験
  30. 2019年, 博士課程・博士課程後期, セメスター(後期), 臨床薬物治療学特別実験
  31. 2019年, 修士課程・博士課程前期, 1ターム, 生命・医療倫理学A
  32. 2019年, 博士課程・博士課程後期, 1ターム, 生命・医療倫理学B
  33. 2019年, 博士課程・博士課程後期, 1ターム, 生命・医療倫理学B
  34. 2019年, 博士課程・博士課程後期, セメスター(前期), 臨床薬物治療学特別演習
  35. 2019年, 博士課程・博士課程後期, セメスター(後期), 臨床薬物治療学特別演習
  36. 2019年, 博士課程・博士課程後期, セメスター(前期), 臨床薬物治療学特別研究
  37. 2019年, 博士課程・博士課程後期, セメスター(後期), 臨床薬物治療学特別研究
  38. 2019年, 修士課程・博士課程前期, セメスター(前期), 薬物治療学特論演習
  39. 2019年, 修士課程・博士課程前期, セメスター(後期), 薬物治療学特論演習
  40. 2019年, 修士課程・博士課程前期, セメスター(前期), 薬物治療学特別研究
  41. 2019年, 修士課程・博士課程前期, セメスター(後期), 薬物治療学特別研究

研究活動

学術論文(★は代表的な論文)

  1. ★, A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography, JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 844巻, 1号, pp. 148-152, NOV 21 2006
  2. ★, High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma, JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 856巻, 1-2号, pp. 371-375, SEP 1 2007
  3. ★, Real-time therapeutic drug monitoring of cefozopran in plasma using high-performance liquid chromatography with ultraviolet detection, JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 45巻, 5号, pp. 811-816, DEC 21 2007
  4. ★, Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients, JOURNAL OF INFECTION AND CHEMOTHERAPY, 16巻, 2号, pp. 139-143, APR 2010
  5. ★, Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 40巻, 5号, pp. 427-433, NOV 2012
  6. ★, Penetration of meropenem into human pancreatic juice, SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 45巻, 5号, pp. 404-406, MAY 2013
  7. ★, Population Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Imipenem Plasma and Urine Data in Neonates and Children, PEDIATRIC INFECTIOUS DISEASE JOURNAL, 32巻, 11号, pp. 1208-1216, NOV 2013
  8. ★, Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: Dosing considerations, PANCREATOLOGY, 14巻, 2号, pp. 95-99, MAR-APR 2014
  9. 医療における将来の薬剤師の役割-香川県在住の薬剤師に対する将来業務に関する意識調査から-(共著), 病院管理, 30巻, 3号, pp. 205-212, 19930401
  10. 医療における将来の薬剤師の役割-香川県在住の薬剤師に対する将来業務に関する意識調査から-, 病院管理, 30巻, 3号, pp. 205-212, 19930401
  11. 外来処方における薬剤投与日数の適正化・・病院管理の再構築に果たす役割・・, 病院管理, 28巻, 3号, pp. 5-12, 19910401
  12. ★, Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy., Biol. Pharm. Bull., 24巻, 4号, pp. 436-438, 20010401
  13. Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy., Biol. Pharm. Bul., 23巻, 6号, pp. 794-787, 20000401
  14. Methotrexate concentration in cerebrospinal fluid of the space created by tumor removal., Biol. Pharm. Bull., 23巻, 6号, pp. 774-777, 20000401
  15. Dose-related increases in cerebrospinal fluid concentrations of methotrexate in a past-surgical patient with glioblastoma., Ann. Pharmacother., 33巻, 9号, pp. 952-956, 19990401
  16. Pharmacokinetical comparison of anticancer drugs in cerebrospinal fluid during cerebrospinal fluid perfusion and injection chemotherapy., Jpn. J. Hosp. Pharm., 25巻, 4号, pp. 376-384, 19990401
  17. Pharmacokinetics of intra-arterially administered methotrexate in plasma and cerebrospinal fluid, Jpn. J. TDM, 16巻, 4号, pp. 387-394, 19990401
  18. Relationship of concentrations of anticancer drugs and duration time during cerebrospinal fluid perfusion chemotherapy., Jpn. J. TDM, 16巻, 3号, pp. 305-313, 19990401
  19. Influences of Concomitant Anticonvulsants on Serum Concentration of Clonazepam in Epileptic Children : An Age- and Dose-effects Linear Regression Model Analysis, Pharm. Pharmacol. Commun., 5巻, 4号, pp. 307-310, 19990401
  20. Pharmacokinetics of Nimustine, Methotrexate, and Cytosine Arabinoside during Cerebrospinal Fluid Perfusion Chemotherapy in Patients with Disseminated Brain Tumors., Eur. J. Clin. Pharmacol., 54巻, 5号, pp. 415-420, 19980401
  21. The Cyanine Dye TriS-C4(5) as a Cationic Uncoupler of Oxidative Phosphorylation with Mitochondria Detected by Derivative Spectrophotometry., Cell Structure and Function, 8巻, pp. 161-170, 19830401
  22. Uncoupling of oxidative phosphorylation by divalent cationic cyanine dye. Participation of phosphate transporter., Biochim= Biophys. Acta, 807巻, pp. 168-176, 19860401
  23. An Escherichia coli mutant exhibiting temperature- sensitive ATP synthesis., Biochem. Biophys. Res. Commun., 138巻, pp. 72-77, 19860401
  24. 注射剤からの塩酸ブプレノルフィン坐剤の調製と性質., 薬剤学, 47巻, pp. 115-123, 19870401
  25. β-carotene の長期服用時の薬物動態, 臨床薬理, 20巻, pp. 625-631, 19890401
  26. テオフィリン新徐放製剤の製剤評価, 診療と新薬, 26巻, pp. 1279-1289, 19890401
  27. 高速液体クロマトグラフィと電気化学検出器によるデノパ  ミンの血中濃度簡便測定法の開発とその臨床応用., 薬学雑誌, 109巻, pp. 858-864, 19890401
  28. メソトレキセートの大量療法時におけるメソトレキセートの血中濃度および尿中濃度の変動, 薬剤学, 50巻, pp. 42-52, 19900401
  29. 単回および持続投与時のthiamylal の体内動態, 薬剤学, 50巻, pp. 245-255, 19900401
  30. 香川医科大学附属病院における体液中薬物濃度測定オ-ダエントリーシステム, 医療情報学, 10巻, pp. 285-293, 19900401
  31. TRH負荷試験による血中プロラクチン濃度の速度論的解析, 核医学, 28巻, pp. 585-590, 19910401
  32. Pharmacokinetics of Methotrexate and 7-Hydroxy-Methotrexate of Patients with High-Dose Methotrexate., Yakuzaigaku, 51巻, pp. 115-122, 19910401
  33. 外来処方における薬剤投与日数の適正化  -病院管理の再構築に果たす役割-, 病院管理, 28巻, pp. 199-207, 19910401
  34. 健常成人におけるクロナゼパム坐剤の薬物動態学的検討., 薬剤学, 51巻, pp. 153-157, 19910401
  35. A Pharmacokinetic Study of Theophylline Following Single Oral Dosing of Sustained-Release Preparations (Theo-Dur)., Jap. J. Hos. Pharm., 17巻, pp. 312-321, 19910401
  36. Gastrin Releasing Peptide (GRP)-like immunoreactive substance in rat mammary glands during pregnancy., Biochem. Biophys. Res. Commun., 180巻, pp. 455-461, 19910401
  37. 自動薬袋印字システムの構築に関する研究., 医療情報学, 11巻, 2号, pp. 111-118, 19910401
  38. 調剤管理システムの構築に関する研究., 医療情報学, 11巻, 3号, pp. 183-196, 19910401
  39. 使用医薬品の実態調査に基づく処方オーダ用診療科別薬品マスターの開発., 医療情報学, 11巻, 3号, pp. 197-204, 19910401
  40. 処方オーダエントリーシステムに関する研究 -特に入力について-, 医療情報学, 11巻, 4号, pp. 243-253, 19910401
  41. 処方オーダエントリーシステムに関する研究 -用法マトリックスの開発-, 医療情報学, 11巻, 4号, pp. 255-262, 19910401
  42. Enzyme immunoassays of AngiotensinⅡ in human plasma., Chem. Pharm. Bull., 40巻, pp. 792-794, 19920401
  43. A Pharmacokinetic Study of Theophylline Following Single Oral Dosing of Sustained-Release Preparations (Theo-Dur) in Fast and after Meals., Yakuzaigaku, 52巻, 2号, pp. 112-119, 19920401
  44. 小児科病棟における医薬品の使用実態調査と医師の意識調査に基づいた薬剤師による服薬指導の検討., 病院薬学, 18巻, 3号, pp. 213-220, 19920401
  45. 急性抗てんかん薬中毒の血液透析・活性炭灌流療法時の薬物動態学的検討., 臨床薬理, 23巻, 2号, pp. 469-474, 19920401
  46. メソトレキセ-ト大量療法における血中濃度シミュレ-ションの有用性., 中部整災誌, 35巻, 3号, pp. 745-746, 19920401
  47. Enzyme linked immunosorbent assay for β-endorphin in human plasma., Chem. Pharm. Bull., 40巻, 7号, pp. 1951-1953, 19920401
  48. 治療抵抗性進行性肺癌患者に対する大量 Etoposide + Cisplatin (CDDP)療法の有用性, 癌と化学療法, 19巻, 6号, pp. 849-854, 19920401
  49. 処置薬請求システムの開発, 九州薬学会報, 46巻, pp. 137-143, 19920401
  50. Effect of terfenadine on the plasma concentrations of substance P and vasoactive intestinal polypeptide in volunteers., J. Pharm. Pharmacol., 44巻, pp. 856-858, 19920401
  51. 調剤管理システム構築とその評価., 病院薬学, 18巻, 6号, pp. 584-593, 19920401
  52. スギ花粉症患者における鼻分泌液中 Substance P, vasoactive intestinal peptide 濃度の季節変動., アレルギ-, 41巻, pp. 1651-1657, 19920401
  53. 病棟活動の質的向上への試み, 病院薬学, 19巻, 2号, pp. 145-151, 19930401
  54. Decrease of Gastrin-releasing peptide-like immunoreactive substance in bronchoalveolary lavage of idopathic pulmonary fibrosis and sarcoidosis., Eur Respir J, 6巻, pp. 418-424, 19930401
  55. 医療における将来の薬剤師の役割-香川県在住の薬剤師に対する将来業務に関する意識調査から-, 病院管理, 30巻, 3号, pp. 205-213, 19930401
  56. Decrease in substance P and vasoactive intestinal peptide(VIP) concentrations in plasma of SHRSP., Jpn. Heart J., 34巻, pp. 509-510, 19930401
  57. 生涯教育に関するアンケ-ト調査, 九州薬学会報, 47巻, pp. 177-187, 19930401
  58. 処方オ-ダエントリシステムにおける処方作成支援機能の評価, 病院薬学, 19巻, pp. 555-566, 19930401
  59. Effects of Terfenadine on substance P and Vasoactive Intestinal Polypeptide Concentrations in Nasal Secretions from Patients with Nasal Allergy, J. Pharm. Pharmacol., 46巻, pp. 41-45, 19940401
  60. バルプロ酸ナトリウム徐放性顆粒剤および錠剤における放出挙動と体内動態の検討., 臨床医薬, 10巻, pp. 1765-1771, 19940401
  61. 大分医科大学病院における院外処方せん発行の経緯, 病院薬学, 20巻, pp. 410-422, 19940401
  62. 病棟活動の質的向上への試み(第2報)-メソトレキセ-ト大量療法時のTDM-, 病院薬学, 20巻, pp. 487-496, 19940401
  63. 薬剤師の意識調査にもとづく調剤業務の電算化に対する評価, 病院薬学, 21巻, pp. 256-264, 19950401
  64. 脳腫瘍患者におけるニムスチン、カルボプラチン、エトポシド併用癌化学療法時の血中およびCSF中薬物動態-動注療法と静注療法時の体内動態の比較-, TDM研究, 13巻, pp. 24-29, 19960401
  65. 病棟活動の質的向上への試み (第3報)-癌化学療法施行時における血中および脳脊髄液中のフェニトインとフェノバルビタ-ルの濃度変化-, 病院薬学, 22巻, pp. 466-472, 19960401
  66. Determination of granisetoron in human plasma by high performance liquid chromatography, Jan. J. Hosp Pharm., 23巻, pp. 31-35, 19970401
  67. 小児てんかん患者に対するClonazepam投与時の血中濃度の評価, 病院薬学, 23巻, pp. 36-42, 19970401
  68. 脳腫瘍患者に対する髄腔内灌流療法時の抗癌剤の薬物動態, TDM研究, 14巻, pp. 162-167, 19970401
  69. Pharmacokinetics of Methotrexate in Plasma and Cerebrospinal Fluid, Ann. Pharmacother., 31巻, pp. 1153-1156, 19970401
  70. Pharmacokinetics of Pirarubicin in Plasma and Cerebrospinal Fluid., Ann. Pharmacother., 32巻, pp. 269, 19980401
  71. Pharmacokinetics of Intra-arterially Administered Pirarubicin in Plasma and Cerebrospinal Fluid of Patients with glioma., Biol. Pharm. Bull., 21巻, pp. 297-299, 19980401
  72. Evaluation of Clonazepam Pharmacokinetics in  Epileptic Children Receiving Monotherapy or Polytherapy, and the Influence of Concomitant Antiepileptic Drugs on the Serum Concentration of Clonazepam., Jpn. J. Hosp. Pharm., 24巻, 2号, pp. 130-135, 19980401
  73. Pharmacokinetics of Antineoplastic Drugs in   Cerebrospinal Fluid during Ventricular and Lumbar   Injection Chemotherapy, Jpn. J. TDM, 15巻, 3号, pp. 272-277, 19980401
  74. Pharmacokinetics of Anticancer Drugs in Cerebrospinal Fluid, Ann. Pharmacother., 32巻, 10号, pp. 1008-1012, 19980401
  75. 病棟活動の質的向上の試み(第4報)-脳腫瘍摘出術を受けた患者に対するZonisamideの血中濃度と術後痙攣発作の予防薬としての価値-, 病院薬学, 24巻, 6号, pp. 673-676, 19980401
  76. Pharmacokinetics of Etoposide in Plasma and Cerebrospinal Fluid in the Space Left by Tumor Removal., Ann. Pharmacother., 33巻, 1号, pp. 115-116, 19990401
  77. 病棟活動の質的向上の試み(第5報)-cyclophosphamide大量投与による末梢血幹細胞動員療法時の血中および脳脊髄液中の薬物動態-, 病院薬学, 25巻, 2号, pp. 112-117, 19990401
  78. Pharmacokinetics of etoposide and carboplatin in cerebrospinal fluid and plasma during hyperosmotic disruption of blood brain barrier and intraarterial combination chemotherapy., Biol. Pharm. Bull., 22巻, 4号, pp. 428-431, 19990401
  79. Influences of Concomitant Anticonvulsants on Serum  Concentration of Clonazepam in Epileptic Children : An Age- and Dose-effects Linear Regression Model Analysis, Pharm. Pharmacol. Commun., 5巻, 4号, pp. 307-310, 19990401
  80. Relationship of concentrations of anticancer drugs and duration time during cerebrospinal fluid perfusion chemotherapy., Jpn. J. TDM, 16巻, 3号, pp. 305-313, 19990401
  81. Pharmacokinetical comparison of anticancer drugs in cerebrospinal fluid during cerebrospinal fluid perfusion and injection chemotherapy., Jpn. J. Hosp. Pharm., 25巻, 4号, pp. 376-384, 19990401
  82. Pharmacokinetics of intra-arterially administered methotrexate in plasma and cerebrospinal fluid, Jpn. J. TDM, 16巻, 4号, pp. 387-394, 19990401
  83. Dose-related increases in cerebrospinal fluid concentrations of methotrexate in a past-surgical patient with glioblastoma., Ann. Pharmacother., 33巻, 9号, pp. 952-956, 19990401
  84. Change of valproic acid concentration in cerebrospinal fluid during cerebrospinal fluid      perfusion chemotherapy., Ann. Pharmacother., 34巻, 4号, pp. 536-537, 20000401
  85. 末梢血幹細胞動員を目的とした抗癌剤大量投与時の抗癌剤の薬物動態, TDM研究, 17巻, 4号, pp. 369-376, 20000401
  86. 精神科でのPOS(Problem Oriented System) を用いた薬剤管理指導業務-九州POS薬剤研究会におけるとりくみ-, 医療薬学, 28巻, 3号, pp. 263-277, 20020401
  87. Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia., Biol. Pharm. Bull., 25巻, 6号, pp. 813-815, 20020401
  88. Microsoft windows XP環境で使用可能な非線形最小二乗法に基づく薬物動態解析プログラム(MULTI-Win)の構築, 医療薬学, 30巻, 7号, pp. 438-444, 20040401
  89. 薬物治療における有害事象早期発見への取り組み, 日本病院薬剤師会雑誌, 39巻, 12号, 20031201
  90. 自己末梢血幹細胞移植におけるメルファランの経口および静脈内投与時の薬物動態の比較, 臨床薬理, 34巻, 2号, pp. 299-300, 20030401
  91. 多発性骨髄腫患者に対するthalidomideの経口投与における薬物動態学的検討, 臨床薬理, 35巻, 1号, pp. 101, 20040401
  92. 抗悪性腫瘍薬の適正使用(ファーマコキネティクスの臨床応用):体内動態、TDM, 臨床薬理, 35巻, 4号, pp. 221-226, 20040401
  93. 開腹手術施行患者における腹水中 Biapenem 動態解析―術後感染を予防するための投与方法の最適化―., 臨床薬理, 36巻, pp. 250S, 20050401
  94. 高齢者喘息患者におけるテオフィリン療法適正化を目指した製剤特性の把握, 薬剤学, 67巻, 198-208号, 20070501
  95. 医療現場でのナノセップの活用法, News Letter “Daiichi”, 11巻, 2-6号, 20061101
  96. Real-time TDMのための簡便かつ迅速なセフォゾプラン測定法の開発, TDM研究, 24巻, S138号, 20070701
  97. ビアペネムのtime above MICを増加させるために点滴時間の延長や点滴回数の増加は有用な手段となるのか?, 臨床薬理, pp. IN PRESS, 20071101
  98. ★, High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma, Journal of Chromatography B, 856巻, pp. 371-375, 20070201
  99. The pharmacokinetics and pharmacodynamics exposure of meropenem in the cerebrospinal fluid of neurosurgical patients., Journal of Chemotherapy, 20巻, 5号, pp. 615-621, 20081001
  100. ★, 多剤耐性緑膿菌に対する抗菌薬3剤の in vitro 併用効果, 日本化学療法学会雑誌, 60巻, 4号, pp. 469-477, 20120701
  101. High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma, Journal of Chromatography B 2007, 856巻, pp. 371-375, 20071201
  102. Dosing regimen rationalization of biapenem in pediatric patients: Use of Monte Carlo simulation, Japanese Journal of Antibiotics, 62巻, pp. 1-8, 20091201
  103. 抗菌薬のPK/PD理論に基づくBiapenemのリアルタイムTDMシステムの構築, TDM研究, 23巻, pp. 229-232, 20060801
  104. ★, 多剤耐性緑膿菌に対するcolistinのin vitro併用効果の検討, 日本臨床腸内微生物学会誌, 16巻, 1号, pp. 48-53, 20140501
  105. ★, 臨床分離薬剤耐性緑膿菌に対する抗菌薬in vitro併用効果 colistin、arbekacin、aztreonam、rifampicin、piperacillinの2剤組合せを用いた比較検討, The Japanese Journal of Antibiotics, 67巻, 3号, pp. 167-174, 20140601
  106. Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: Comparisons with famotidine, DIGESTIVE DISEASES AND SCIENCES, 51巻, 1号, pp. 114-120, JAN 2006
  107. Calcitonin gene-related peptide and somatostatin releases correlated with the area under the lafutidine concentration-time curve in human plasma, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 31巻, 4号, pp. 351-356, AUG 2006
  108. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: Comparison with Famotidine, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 30巻, 5号, pp. 1003-1006, MAY 2007
  109. The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 29巻, 11号, pp. 2331-2334, NOV 2006
  110. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers, DIGESTIVE DISEASES AND SCIENCES, 52巻, 2号, pp. 390-395, FEB 2007
  111. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 30巻, 3号, pp. 270-273, SEP 2007
  112. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 30巻, 4号, pp. 352-355, OCT 2007
  113. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients, JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60巻, 6号, pp. 1395-1397, DEC 2007
  114. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 33巻, 6号, pp. 677-684, DEC 2008
  115. Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 33巻, 2号, pp. 203-210, APR 2008
  116. Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients, CHEMOTHERAPY, 54巻, 2号, pp. 131-139, 2008
  117. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis, JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61巻, 4号, pp. 892-900, APR 2008
  118. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection, JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 867巻, 1号, pp. 20-25, MAY 1 2008
  119. Penetration and exposure of cefotiam into the peritoneal fluid of abdominal surgery patients after intravenous administration, JOURNAL OF CHEMOTHERAPY, 20巻, 3号, pp. 319-323, JUN 2008
  120. Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 32巻, 4号, pp. 339-343, OCT 2008
  121. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 33巻, 3号, pp. 276-279, MAR 2009
  122. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: A dosing strategy, CHEMOTHERAPY, 54巻, 5号, pp. 386-394, 2008
  123. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation, DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 62巻, 3号, pp. 292-297, NOV 2008
  124. The Pharmacokinetics and Pharmacodynamics of Meropenem in the Cerebrospinal Fluid of Neurosurgical Patients, JOURNAL OF CHEMOTHERAPY, 20巻, 5号, pp. 615-621, OCT 2008
  125. Determination of total cefozopran concentrations in human peritoneal fluid by HPLC with cefepime as an internal standard: Comparative pharmacokinetics in the fluid and plasma, JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 49巻, 4号, pp. 1075-1081, MAY 1 2009
  126. LC Method for the Determination of Meropenem in Cerebrospinal Fluid: Application to Therapeutic Drug Monitoring, CHROMATOGRAPHIA, 69巻, 9-10号, pp. 1031-1034, MAY 2009
  127. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 34巻, 1号, pp. 91-94, JUL 2009
  128. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections, JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64巻, 4号, pp. 840-844, OCT 2009
  129. ★, Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 35巻, 5号, pp. 504-506, MAY 2010
  130. Pharmacokinetics and pharmacodynamics of once-daily arbekacin during continuous venovenous hemodiafiltration in critically ill patients, JOURNAL OF INFECTION AND CHEMOTHERAPY, 15巻, 6号, pp. 420-423, DEC 2009
  131. Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients, JOURNAL OF INFECTION AND CHEMOTHERAPY, 16巻, 1号, pp. 25-32, FEB 2010
  132. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections, JOURNAL OF INFECTION AND CHEMOTHERAPY, 16巻, 3号, pp. 193-199, JUN 2010
  133. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 36巻, 2号, pp. 179-181, AUG 2010
  134. LC Determination of Total Cefotiam Concentration in Human Serum: Application of Ultrafiltration to a High Protein-Binding Drug, CHROMATOGRAPHIA, 72巻, 1-2号, pp. 157-162, JUL 2010
  135. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication, JOURNAL OF INFECTION AND CHEMOTHERAPY, 17巻, 2号, pp. 297-300, APR 2011
  136. Prostatic Penetration of Meropenem after Intravenous Administration in Patients Undergoing Transurethral Resection of the Prostate, JOURNAL OF CHEMOTHERAPY, 23巻, 3号, pp. 179-180, JUN 2011
  137. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 38巻, 5号, pp. 417-420, NOV 2011
  138. Clinical Pharmacokinetics of Meropenem and Biapenem in Bile and Dosing Considerations for Biliary Tract Infections Based on Site-Specific Pharmacodynamic Target Attainment, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55巻, 12号, pp. 5609-5615, DEC 2011
  139. Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation, JOURNAL OF CHEMOTHERAPY, 24巻, 1号, pp. 32-37, FEB 2012
  140. Reduction in the incidence of MRSA with use of alcohol-based hand rub solutions and gloves, JOURNAL OF INFECTION AND CHEMOTHERAPY, 18巻, 2号, pp. 269-271, APR 2012
  141. Significant Association between Hand-Foot Syndrome and Efficacy of Capecitabine in Patients with Metastatic Breast Cancer, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 35巻, 5号, pp. 717-724, MAY 2012
  142. Development and validation of a GC-EI-MS method with reduced adsorption loss for the quantification of olanzapine in human plasma, ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 403巻, 7号, pp. 1823-1830, JUN 2012
  143. Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery, JOURNAL OF INFECTION AND CHEMOTHERAPY, 18巻, 6号, pp. 878-882, DEC 2012
  144. Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 41巻, 3号, pp. 267-271, MAR 2013
  145. Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics, JOURNAL OF INFECTION AND CHEMOTHERAPY, 19巻, 1号, pp. 98-102, FEB 2013
  146. Development of Initial Loading Procedure for Teicoplanin in Critically Ill Patients with Severe Infections, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 36巻, 6号, pp. 1024-1026, JUN 2013
  147. ★, Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 43巻, 6号, pp. 547-552, JUN 2014
  148. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 44巻, 3号, pp. 242-247, SEP 2014
  149. Pharmacokinetics and pharmacodynamic target attainment of intravenous pazufloxacin in the bile of patients undergoing biliary pancreatic surgery, JOURNAL OF CHEMOTHERAPY, 26巻, 5号, pp. 287-292, OCT 2014
  150. ★, Factors Affecting Treatment and Recurrence of Clostridium difficile Infections, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 37巻, 11号, pp. 1811-1815, NOV 2014
  151. ★, Risk Factors for Ganciclovir-Induced Thrombocytopenia and Leukopenia, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 38巻, 2号, pp. 235-238, FEB 2015
  152. ★, Nephrotoxicity Induced by Piperacillin-Tazobactam in Late Elderly Japanese Patients with Nursing and Healthcare Associated Pneumonia, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 37巻, 12号, pp. 1971-1976, DEC 2014
  153. ★, Health Assessment of Local Residents Who Made Full Use of Symptomatology Skills and Test Device, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 135巻, 2号, pp. 175-179, FEB 2015
  154. ★, Gas chromatography-electron ionization-mass spectrometry quantitation of valproic acid and gabapentin, using dried plasma spots, for therapeutic drug monitoring in in-home medical care, BIOMEDICAL CHROMATOGRAPHY, 28巻, 12号, pp. 1756-1762, DEC 2014
  155. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics, JOURNAL OF INFECTION AND CHEMOTHERAPY, 21巻, 1-2号, pp. 70-73, JAN-FEB 2015
  156. ★, Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: Dosing considerations for Acinetobacter baumannii infections, JOURNAL OF INFECTION AND CHEMOTHERAPY, 21巻, 3-4号, pp. 284-289, MAR-APR 2015
  157. ★, Pharmacokinetics and skin-tissue penetration of daptomycin in rats., Clinical pharmacology : advances and applications, 7巻, 2015
  158. ★, Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 21巻, 6号, 2015
  159. ★, Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 21巻, 4号, 2015
  160. ★, Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients., International journal of antimicrobial agents, 44巻, 3号, 2014
  161. ★, Gas chromatography-electron ionization-mass spectrometry quantitation of valproic acid and gabapentin, using dried plasma spots, for therapeutic drug monitoring in in-home medical care., Biomedical chromatography : BMC, 28巻, 12号, 2014
  162. ★, Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models., International journal of antimicrobial agents, 43巻, 6号, 2014
  163. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations., Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 14巻, 2号
  164. Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children., The Pediatric infectious disease journal, 32巻, 11号, 2013
  165. Penetration of meropenem into human pancreatic juice., Scandinavian journal of infectious diseases, 45巻, 5号, 2013
  166. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data., International journal of antimicrobial agents, 40巻, 5号, 2012
  167. Development and validation of a GC-EI-MS method with reduced adsorption loss for the quantification of olanzapine in human plasma., Analytical and bioanalytical chemistry, 403巻, 7号, 2012
  168. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment., Antimicrobial agents and chemotherapy, 55巻, 12号, 2011
  169. HPLC method for measuring meropenem and biapenem concentrations in human peritoneal fluid and bile: application to comparative pharmacokinetic investigations., Journal of chromatographic science, 48巻, 5号
  170. Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 16巻, 2号, 2010
  171. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 16巻, 1号, 2010
  172. Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients., The Japanese journal of antibiotics, 62巻, 5号, 2009
  173. Pharmacokinetics and pharmacodynamics of once-daily arbekacin during continuous venovenous hemodiafiltration in critically ill patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 15巻, 6号, 2009
  174. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections., The Journal of antimicrobial chemotherapy, 64巻, 4号, 2009
  175. [Dosing regimen rationalization of biapenem in pediatric patients: use of Monte Carlo simulation]., The Japanese journal of antibiotics, 62巻, 1号, 2009
  176. Determination of total cefozopran concentrations in human peritoneal fluid by HPLC with cefepime as an internal standard: Comparative pharmacokinetics in the fluid and plasma., Journal of pharmaceutical and biomedical analysis, 49巻, 4号, 2009
  177. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients., International journal of antimicrobial agents, 33巻, 3号, 2009
  178. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy., Chemotherapy, 54巻, 5号, 2008
  179. Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14巻, 4号, 2008
  180. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation., Diagnostic microbiology and infectious disease, 62巻, 3号, 2008
  181. Penetration into and exposure of cefozopran in pelvic retroperitoneal space exudate., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14巻, 2号, 2008
  182. Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14巻, 2号, 2008
  183. Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14巻, 2号, 2008
  184. Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14巻, 2号, 2008
  185. Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation., International journal of antimicrobial agents, 32巻, 4号, 2008
  186. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 867巻, 1号, 2008
  187. Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients., Chemotherapy, 54巻, 2号, 2008
  188. Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14巻, 1号, 2008
  189. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients., The Journal of antimicrobial chemotherapy, 60巻, 6号, 2007
  190. Real-time therapeutic drug monitoring of cefozopran in plasma using high-performance liquid chromatography with ultraviolet detection., Journal of pharmaceutical and biomedical analysis, 45巻, 5号, 2007
  191. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients., International journal of antimicrobial agents, 30巻, 4号, 2007
  192. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients., International journal of antimicrobial agents, 30巻, 3号, 2007
  193. High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 856巻, 1-2号, 2007
  194. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine., Biological & pharmaceutical bulletin, 30巻, 5号, 2007
  195. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers., Digestive diseases and sciences, 52巻, 2号, 2007
  196. The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma., Biological & pharmaceutical bulletin, 29巻, 11号, 2006
  197. A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 844巻, 1号, 2006
  198. Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine., Digestive diseases and sciences, 51巻, 1号, 2006
  199. ★, Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2015
  200. ★, Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 21巻, 1号, 2015
  201. ★, Evaluation of a pharmacokinetic-pharmacodynamic approach using software to optimize the carbapenem antibiotic regimen, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 53巻, 6号, pp. 422-429, JUN 2015
  202. ★, Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis, JOURNAL OF INFECTION AND CHEMOTHERAPY, 21巻, 5-6号, pp. 476-478, MAY-JUN 2015
  203. ★, Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics, JOURNAL OF INFECTION AND CHEMOTHERAPY, 21巻, 8号, pp. 575-580, AUG 2015
  204. ★, Pharmacokinetics of Prophylactic Ampicillin Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 38巻, 11号, pp. 1817-1821, NOV 2015
  205. ★, Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations., Pancreatology, 14巻, pp. 95-99, 2014
  206. ★, Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models., Int. J. Antimicrob. Agents, 43巻, pp. 547-552, 2014
  207. ★, Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients., Int. J. Antimicrob. Agents, 44巻, pp. 242-247, 2014
  208. ★, Gas chromatography-electron ionization-mass spectrometry quantitation of valproic acid and gabapentin, using dried plasma spots, for therapeutic drug monitoring in in-home medical care., Biomed. Chromatogr., 28巻, pp. 1756-1762, 2014
  209. ★, Factors affecting treatment and recurrence of Clostridium difficile infections., Biol. Pharm. Bull., 37巻, pp. 1811-1815, 2014
  210. ★, Pharmacokinetics and pharmacodynamic target attainment of intravenous pazufloxacin in the bile of patients undergoing biliary pancreatic surgery., J. Chemother., 26巻, pp. 287-292, 2014
  211. ★, Nephrotoxicity induced by piperacillin-tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia., Biol. Pharm. Bull., 37巻, 1号, pp. 1971-1976, 2014
  212. ★, Pharmacokinetic modeling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages., J. Clin. Pharm. Ther., 39巻, 1号, pp. 411-417, 2014
  213. ★, 多剤耐性緑膿菌に対する colistin の in vitro 併用効果の検討., 日本臨床腸内微生物学会誌, 16巻, pp. 48-53, 2014
  214. ★, 臨床分離薬剤耐性緑膿菌に対する抗菌薬 in vitro 併用効果~colistin, arbekacin, aztreonam, rifampicin, piperacillin の 2 剤組合せを用いた比較検討~., Jpn. J. Antibiot., 67巻, pp. 167-174, 2014
  215. ★, The pharmacokinetics of ampicillin-sulbactam in anuric patients: dosing optimization for prophylaxis during cardiovascular surgery, INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 38巻, 4号, pp. 771-775, AUG 2016
  216. ★, Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data, JOURNAL OF CHEMOTHERAPY, 28巻, 3号, pp. 198-202, 2016
  217. ★, Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections, CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 8巻, 2016
  218. ★, Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations, CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 9巻, pp. 39-44, 2017
  219. ★, Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue, JOURNAL OF INFECTION AND CHEMOTHERAPY, 23巻, 4号, pp. 214-217, APR 2017
  220. ★, Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis, JOURNAL OF INFECTION AND CHEMOTHERAPY, 23巻, 12号, pp. 809-813, DEC 2017
  221. ★, Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 50巻, 3号, pp. 393-398, SEP 2017
  222. ★, Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 51巻, 5号, pp. 745-751, MAY 2018
  223. ★, Pharmacokinetics and skin-tissue penetration of daptomycin in rats, CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 7巻, pp. 79-82, 2015